Contributing to this collaboration, Delta 4 will apply its proprietary computational and iterative big data analytics platform to identify novel therapeutic targets and signaling pathways as well as drug candidates for a rare autoimmune chronic liver disease. Based on the results provided by Delta 4, 4P-Pharma will structure a tailored R&D maturation program with the focus to further characterize these candidates to demonstrate their potential for improving the treatment. Together, Delta 4’s and 4P-Pharma’s teams aim to bring an innovative drug candidate to patients affected by this rare disease.

“4P-Pharma aims to bring breakthrough curative solutions with a strong scientific rationale to patients”, stated Revital Rattenbach, CEO of 4P-Pharma. “With this partnership, we will benefit from Delta 4’s AI proprietary computational analytics platform to identify breakthrough drug candidates. Combined with our drug development expertise, together we will accelerate the identification of drug candidates for patients affected by this rare liver disease. It underlines our shared commitment to bring breakthrough solutions to patients.”

“We are looking forward to joining forces with 4P-Pharma to make a difference for patients who are suffering from a devastating disease”, commented Kurt Herpel, CEO, Delta 4. Herpel added: “4P-Pharma has consistently proven the viability of their rigorous and focused approach to advancing promising drug candidates up the development pipeline. Specifically, we are excited about the opportunity to apply our platform to a new disease area and to work with 4P-Pharma to make a difference in the treatment of these liver impaired patients.”